25 November 2025

Ortiv-Q3 successfully inspected by the US-FDA

Our SOTAX Pharma Services laboratory in India has successfully cleared the US-FDA RRA inspection without a single observation – setting a new benchmark for quality and compliance.

We are proud to announce that Ortiv-Q3, our state-of-the-art laboratory operated by SOTAX Pharma Services in India, has achieved a significant milestone: US-FDA approval with zero observations during the recent RRA inspection.

This accomplishment reflects our unwavering commitment to quality, regulatory excellence, and customer trust. By meeting the highest international standards, Ortiv-Q3 strengthens its position as a reliable partner for pharmaceutical testing and services worldwide.

Learn more about our capabilities and how we can support your projects at ortiv.sotax.com or meet us at CPHI PMEC India.